Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma.

Vieira Neto L, Chimelli L, Pereira PJ, Gasparetto EL, Bines J, Wildemberg LE, Gadelha MR.

Endocr Pract. 2013 Nov-Dec;19(6):e145-9. doi: 10.4158/EP12400.CR.

PMID:
23807517
2.

Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.

Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P.

Clin Endocrinol (Oxf). 2007 Aug;67(2):282-9. Epub 2007 May 24.

3.

Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.

Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T.

Endocr J. 2006 Feb;53(1):125-32.

4.
5.

Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.

Ghazi AA, Rotondo F, Kovacs K, Amirbaigloo A, Syro LV, Fathalla H, Di Ieva A, Cusimano MD.

Endocr Pathol. 2015 May;26(2):135-9. doi: 10.1007/s12022-015-9361-z. Review.

PMID:
25716461
6.

Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.

Schoof E, Dörr HG, Kiess W, Lüdecke DK, Freitag E, Zindel V, Rascher W, Dötsch J.

Horm Res. 2004;61(4):184-9. Epub 2004 Jan 23.

PMID:
14739526
7.

Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.

Lundin P, Edén Engström B, Karlsson FA, Burman P.

AJNR Am J Neuroradiol. 1997 Apr;18(4):765-72.

8.

Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?

Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.

Clin Endocrinol (Oxf). 2007 Aug;67(2):310-5. Epub 2007 Jun 6.

PMID:
17555503
9.

Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.

Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K.

Hormones (Athens). 2009 Oct-Dec;8(4):303-6.

10.

Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.

Shimon I, Nass D, Hadani M.

Pituitary. 2000 May;2(4):289-94.

PMID:
11081151
11.

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J; SMS995B2401 Study Group.

Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68. Epub 2007 Apr 25.

12.

Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.

Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.

Horm Res. 2004;62(5):227-32. Epub 2004 Oct 11.

PMID:
15477693
13.

First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.

Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.

Clin Endocrinol (Oxf). 2006 Mar;64(3):342-51.

PMID:
16487447
14.

Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.

Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol PF, Kemeny JL, Chazal J, Trouillas J, Tauveron I.

Cancer Invest. 2013 Mar;31(3):190-6. doi: 10.3109/07357907.2013.775293.

PMID:
23477586
15.

Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.

Yin J, Su CB, Xu ZQ, Yang Y, Ma WB, Tao W, Yang Z, Xia XW.

Chin Med Sci J. 2005 Mar;20(1):23-6.

PMID:
15844307
16.

Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study.

Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A, Ragazzoni F, Pigliaru F, Alberti D, Ferrara R, Angeletti G.

J Endocrinol Invest. 2005 Dec;28(11):978-83.

PMID:
16483175
17.

Thyrotropin secreting pituitary adenoma accompanying a silent somatotropinoma.

Berker D, Isik S, Aydin Y, Tutuncu Y, Akdemir G, Ozcan HN, Guler S.

Turk Neurosurg. 2011;21(3):403-7. doi: 10.5137/1019-5149.JTN.2642-09.2.

18.

Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.

Plöckinger U, Quabbe HJ.

Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. Epub 2005 Apr 4.

PMID:
15806331
19.

Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR.

Resmini E, Murialdo G, Giusti M, Boschetti M, Minuto F, Ferone D.

J Endocrinol Invest. 2005 Feb;28(2):166-9.

PMID:
15887864
20.

Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.

Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, Li S, Zhao Y.

Endocr J. 2010;57(12):1035-44. Epub 2010 Nov 16.

Items per page

Supplemental Content

Write to the Help Desk